1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Rare Neurological Disease Treatment Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Rare Neurological Disease Treatment Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Innovative Therapies Rare Neurological Disease Treatment
5.2 Market Opportunities
- 5.2.1 Product Launches to Favor Market
5.3 Future Trends
- 5.3.1 Clinical trials and drug research to treat rare neurological disease treatment
5.4 Impact of Drivers and Restraints
6. North America Rare Neurological Disease Treatment Market Regional Analysis
6.1 North America Rare Neurological Disease Treatment Market Overview
6.2 North America Rare Neurological Disease Treatment Market Revenue 2017-2027 (US$ Million)
6.3 North America Rare Neurological Disease Treatment Market Forecast Analysis
7. North America Rare Neurological Disease Treatment Market Analysis – by Indication
7.1 Narcolepsy
- 7.1.1 Overview
- 7.1.2 Narcolepsy: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Amyotrophic Lateral Sclerosis
- 7.2.1 Overview
- 7.2.2 Amyotrophic Lateral Sclerosis: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Alzheimer's Disease
- 7.3.1 Overview
- 7.3.2 Alzheimer's Disease: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Multiple Sclerosis
- 7.4.1 Overview
- 7.4.2 Multiple Sclerosis: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Spinal Muscular Atrophy
- 7.5.1 Overview
- 7.5.2 Spinal Muscular Atrophy: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Duchenne Muscular Dystrophy
- 7.6.1 Overview
- 7.6.2 Duchenne Muscular Dystrophy: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Other Indication
- 7.7.1 Overview
- 7.7.2 Other Indication: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Rare Neurological Disease Treatment Market Analysis – by Drug Type
8.1 Organic Compounds
- 8.1.1 Overview
- 8.1.2 Organic Compounds: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Biologics
- 8.2.1 Overview
- 8.2.2 Biologics: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
9. North America Rare Neurological Disease Treatment Market Analysis – by Distribution Channel
9.1 Online Pharmacies
- 9.1.1 Overview
- 9.1.2 Biologics: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Hospital Pharmacies
- 9.2.1 Overview
- 9.2.2 Biologics: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Biologics: North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
10. North America Rare Neurological Disease Treatment Market – North America Analysis
10.1 North America
- 10.1.1 North America Rare Neurological Disease Treatment Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 North America Rare Neurological Disease Treatment Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 US:
North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 US: North America Rare Neurological Disease Treatment Market Breakdown, by Indication
- 10.1.1.1.2 US: North America Rare Neurological Disease Treatment Market Breakdown, by Drug Type
- 10.1.1.1.3 US: North America Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel
- 10.1.1.2 Canada:
North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 Canada: North America Rare Neurological Disease Treatment Market Breakdown, by Indication
- 10.1.1.2.2 Canada: North America Rare Neurological Disease Treatment Market Breakdown, by Drug Type
- 10.1.1.2.3 Canada: North America Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel
- 10.1.1.3 Mexico :
North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 Mexico : North America Rare Neurological Disease Treatment Market Breakdown, by Indication
- 10.1.1.3.2 Mexico : North America Rare Neurological Disease Treatment Market Breakdown, by Drug Type
- 10.1.1.3.3 Mexico : North America Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. North America Rare Neurological Disease Treatment Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Allergan plc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Bayer AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Johnson & Johnson Services Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck & Co. Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Novartis AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Pfizer Inc.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Sanofi
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Teva Pharmaceutical Industries Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Takeda Pharmaceutical Company Limited
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For North America Rare Neurological Disease Treatment Market
